Abstract
The XRCC3 variant T241M, but not D213N, has been reported to be associated with an increased risk of some cancers. XRCC3 is one out of five RAD51 paralogues and is involved in homologous recombination, as are the BRCA1 and BRCA2 proteins. However, in contrast to mutations in BRCA1 and BRCA2, the XRCC3(T241M) protein is proficient in homologous recombination and reverts sensitivity to mitomycin C found in XRCC3-deficient cells, whereas XRCC3(D213N) is defective in homologous recombination. Here, we report that both the XRCC3 D213N and T241M alleles are associated with an increase in centrosome number and binucleated cells. However, only the D213N allele gives an increase in spontaneous levels of apoptosis. We suggest that the inability of XRCC3 T241M to apoptotically eliminate aberrant cells with mitotic defects could increase cancer susceptibility in individuals carrying this variant. In contrast, cells carrying the XRCC3 D213N variant are able to eliminate aberrant cells by apoptosis, and consistent with this observation, this variant does not seem to be associated with cancer susceptibility.
References
Nov 1, 1995·The Journal of Experimental Medicine·S J MartinD R Green
Jul 3, 1995·Proceedings of the National Academy of Sciences of the United States of America·R S TebbsL H Thompson
Mar 1, 1994·Mutagenesis·N Schultz, A Onfelt
Apr 24, 1997·Nature·K W Kinzler, B Vogelstein
May 15, 1997·Genes & Development·T LudwigA Efstratiadis
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·L C Hsu, R L White
Jan 1, 1999·Nature·C LengauerB Vogelstein
Apr 13, 1999·Molecular Cell·X XuC X Deng
Feb 8, 2002·Cell·Ashok R Venkitaraman
May 31, 2002·Oncogene·Felipe D AraujoMaria Jasin
Feb 14, 2003·Carcinogenesis·John M HinzMark Meuth
Apr 2, 2003·Human Molecular Genetics·Saeed RafiiAngela Cox
Aug 3, 2004·Oncogene·Celia VogelHolger Bastians
Sep 18, 2004·Science·Matthew J DanielsAshok R Venkitaraman
Citations
Oct 26, 2006·Breast Cancer Research and Treatment·Sandra CostaFernando Schmitt
Dec 17, 2009·Cancer Epidemiology·Susana N SilvaJorge Francisco Gaspar
Nov 23, 2007·Leukemia·D BhatlaUNKNOWN Children's Oncology Group
Jul 2, 2010·DNA and Cell Biology·Raju K MandalRama Devi Mittal
Jun 28, 2011·Carcinogenesis·Tasha R SmithJennifer J Hu
May 28, 2009·Molecular and Cellular Biology·Ganesh NagarajuRalph Scully
Aug 21, 2007·BMC Cancer·M Felicitas López-CimaAdonina Tardón
May 24, 2006·Nucleic Acids Research·Claudia WieseDavid Schild
Nov 27, 2007·Mutation Research·G IarmarcovaiT Orsière
Jan 3, 2007·Mutation Research·G IarmarcovaiT Orsière
Mar 31, 2009·International Journal of Cancer. Journal International Du Cancer·Keke ZhouLiangfu Zhou
Aug 30, 2008·American Journal of Hematology·Lisa M Baumann Kreuziger, David P Steensma
Oct 26, 2011·Journal of Applied Toxicology : JAT·Maria EfthimiouSotiris S Nikolaropoulos
Jan 29, 2013·Environmental and Molecular Mutagenesis·Carina LadeiraMiguel Brito
Oct 13, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Charlotta RykSai-Mei Hou
Jul 21, 2006·Toxicology Letters·G IarmarcovaiT Orsière
Jan 30, 2009·Cell Cycle·Rachel William Anantha, James A Borowiec
Feb 8, 2011·Leukemia Research·Liang LiuZhijian Xiao
Sep 19, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Qian CuiJin-Xin Bei
Oct 10, 2009·Mutation Research·Ruchika GangwarRama Devi Mittal
Jul 15, 2017·The International Journal of Biological Markers·Sílvia SoaresRui Medeiros
Jul 24, 2018·Oral Diseases·Edilmar de Moura SantosRoseana de Almeida Freitas
Apr 8, 2019·Radiation and Environmental Biophysics·Mahsa ShakeriMohammad Reza Farshidpour
Apr 14, 2018·Indian Journal of Clinical Biochemistry : IJCB·Raju Kumar Mandal, Rama Devi Mittal
May 17, 2008·Cancer Research·Haomin HuangRuth J Muschel